Metabolic dysfunction-associated steatotic liver disease in children

Area of Science:

• Pediatric Hepatology
• Metabolic Disorders
• Public Health

Background:

• Metabolic dysfunction-associated steatotic liver disease (MASLD) is the predominant chronic liver disease in pediatric populations.
• The incidence of MASLD is escalating globally, closely linked to the rising rates of childhood obesity, affecting up to 40% of obese children.
• MASLD poses significant long-term health risks if not managed effectively in early life.

Purpose of the Study:

• To outline current diagnostic criteria for MASLD in children and adolescents.
• To review and evaluate potential biomarkers for early screening of MASLD in pediatric cohorts.
• To propose evidence-based treatment and management strategies for pediatric MASLD.

Main Methods:

• Review of existing literature on pediatric MASLD diagnosis and management.
• Analysis of studies investigating novel screening markers for MASLD in children.
• Synthesis of current treatment guidelines and recommendations for pediatric MASLD.

Main Results:

• Established diagnostic criteria for MASLD in pediatric patients are presented.
• Several promising screening markers for early detection of MASLD in children are identified.
• A comprehensive approach to MASLD treatment, including lifestyle modifications and pharmacological options, is suggested.

Conclusions:

• Accurate diagnosis and early screening are crucial for managing pediatric MASLD.
• Effective management strategies are essential to mitigate the long-term consequences of MASLD in children.
• Continued research into novel biomarkers and therapeutic interventions is warranted for pediatric MASLD.